You are here

Share:

Product Type

Development Stage

Therapeutic Area

Institutes and Centers

Search Technologies

Showing 1-18 of 18 results found

Clinical Outcome Predictors for Mantle Cell Lymphoma

The invention is a novel methodology for predicting a mantle cell lymphoma (MCL) cancer patient’s survival prognosis. This information is important in helping determine the best course of treatment for the patient.
  • Diagnostics

Conserved Elements Vaccine for HIV

Researchers at the National Cancer Institute (NCI) developed a DNA vaccine using conserved elements of HIV-1 Gag, administered in a prime-boost vaccination protocol. Two of the HIV Gag CE DNA vectors have been tested in a rhesus macaque model. Priming with the Gag CE vaccine and boosting with full length Gag DNA showed increased immune responses when compared to vaccination with Gag alone. Researchers seek licensing and/or co-development research collaborations for development this DNA vaccine.
  • Vaccines

Diagnostic Assay for Determining Patient Response to Apoptosis-related Cancer Therapy

Researchers at the National Cancer Institute (NCI) developed a multiplex assay to determine the efficacy of apoptosis-related drugs targeting the Bcl2 family of proteins or aid in the selection of cancer patients likely to respond. The NCI seeks partners for co-development or licensees for commercialization of novel immunoassays for determining or predicting patient response to cancer therapy.
  • Diagnostics

Methods of analyzing virus-derived therapeutics

Researchers at the National Cancer Institute’s Biopharmaceutical Development Program recently developed massively parallel sequencing methods for virus-derived therapeutics such as viral vaccines and oncolytic immunotherapies, for which the NCI seeks licensees or co-development collaborations.
  • Diagnostics

Mobile Software for Substance Abuse Interventions and Behavioral Modification

Researchers at the National Institute on Drug Abuse (NIDA) seek licensing and/or co-development research collaborations to further develop, evaluate or commercialize the software, Mobile Personalized Assessment & Learning for Addiction Treatment and Behavioral Modification. NIDA researchers developed this software for use in treating substance use disorders (drugs, alcohol, smoking) that provides personalized feedback to users.
  • Software

Newly Improved Method and Composition for Treating Genetically Linked Diseases of the Eye

To improve the transduction efficiency the inventors at the National Eye Institute (NEI) have developed a novel, non-invasive approach of applying electric current in combination with a gene therapy vector. This minimally invasive strategy significantly improves the transduction efficiency of AAV vectors in the mouse retina. This represents an improved method for restoring high levels of RS1 expression in the retina of X-linked retinoschisis (XLRS) patients. The NEI seeks a licensing and/or co-development partner to commercialize its AAV-RS1 Gene Therapy for XLRS.
  • Therapeutics

Non-invasive diagnostic and prognostic assay for early stage lung cancer

NCI scientists developed a method that uses urine samples to detect early-stage cancers and that could supplement low-dose computed tomography (LD-CT) to significantly decrease its expensive false negative/false positive results, and the NCI seeks co-developers or licensees to commercialize this technology.
  • Diagnostics

Processes for Producing and Purifying Nucleic Acid-Containing Compositions

This technology provides improved processes for production and purification of nucleic acid-containing compositions, such as non-naturally occurring viruses, for example, recombinant polioviruses that can be employed as oncolytic agents. Some of the improved processes relate to improved processes for producing viral DNA template.
  • Therapeutics

Rapid Manufacture of Retroviral Vectors Encoding Tumor-Specific T Cell Receptors for Adoptive Cell Immunotherapy

Researchers at the National Cancer Institute (NCI) have developed a novel method enabling rapid, GMP-compliant manufacture of retroviral vectors encoding anti-tumor T cell receptors (TCRs). T cells engineered through the use of these vectors to express tumor-reactive TCRs will be useful in adoptive cell immunotherapy for the treatment of cancer. Researchers at the NCI seek licensing and/or co-development research collaborations for this invention.
  • Therapeutics

SLCO1B3 Genotyping to Predict a Survival Prognosis of Prostate Cancer

This invention identifies two polymorphic genetic markers in the SLCO1B3 (formerly SLC21A8) gene, called 334T>G and 699G>A, that can be measured in genomic DNA obtained from a blood sample to predict survival from diagnosis of prostate cancer in that individual patient.
  • Diagnostics

T Cell Receptors Targeting KRAS Mutants for Cancer Immunotherapy/Adoptive Cell Therapy

Researchers at the National Institutes of Health have identified a collection of TCRs that specifically target mutated KRAS antigen. These TCRs exclusively recognize the G12D or G12V variants of mutated KRAS, which are common hotspot driver mutations expressed by a variety of epithelial cancers, including pancreatic, colorectal and lung cancer. The mutated KRAS variants are recognized by the TCRs in the context of HLA-A*11:01 or HLA-C*08:02. These TCRs can be used for a variety of experimental therapeutic, diagnostic and research applications.
  • Therapeutics

T-Cell Therapy Against Patient-Specific Cancer Mutations

Scientists at the National Cancer Institute developed a method to identify T cells that specifically recognize immunogenic mutations expressed only by cancer cells. NCI seeks parties interested in collaborative research to co-develop or license T-cell therapy against cancer mutations
  • Therapeutics

Therapeutics for Neurodegenerative Disorders and Cancer Using Lenalidomide Analogs

Novel thalidomide analogs and their use as immunomodulatory agents are disclosed in this invention by scientists at the National Institute on Aging (NIA). These therapeutic compounds could reduce chronic systemic and central nervous system inflammation. The NIA seeks licensing or co-development partners to commercialize this technology.
  • Therapeutics

Topical Sodium Nitrate Ointment for Sickle Cell Disease

The National Institutes of Health, through The National Institutes of Health - Clinical Center (NIH-CC) and the National Heart Lung and Blood Institute (NHLBI), seeks licensing and/or co-development partners for a nitric oxide cream for the treatment of ulcers associated with sickle cell disease.
  • Therapeutics